Low Dose PEM Results Presented at ECR 2012
Study Shows Positron Emission Mammography With 50% Less Radiation Has Same Sensitivity
(firmenpresse) - VIENNA, AUSTRIA -- (Marketwire) -- 03/01/12 -- Presented today at the European Congress of Radiology (ECR) in Vienna, Austria, researchers from Boca Raton Regional Hospital in Florida showed that FDG dose for Positron Emission Mammography (PEM) may be reduced by up to 50% without impacting sensitivity. Several clinical cases utilizing an optimized dose were presented as part of this abstract.
"These results are extremely exciting and have immediately impacted my clinical practice," said Dr. Kathy Schilling, Medical Director of the Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital. "In this era of cautiously using radiation, I have responded by lowering the dose by one half for my patients without compromising image quality and diagnostic ability."
PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term "specificity." Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only FDA-cleared, CE-certified 3D Molecular Breast Imaging (MBI) device on the market with biopsy-guidance.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and is globally distributed in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.
Guillaume Bailliard
Executive Vice President
Naviscan, Inc.
Tel: +1.858.332.0941
Joleen Schultz
Naviscan Marketing Communications
321 Medical Launch
Tel: +1.858.455.5500
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.03.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 120428
Anzahl Zeichen: 2614
contact information:
Town:
VIENNA, AUSTRIA
Kategorie:
Women's Interest
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Low Dose PEM Results Presented at ECR 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Naviscan (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
